Compare Kimco Realty Corporation (HC) Common Stock (KIM) vs Maravai LifeSciences Holdings Inc. Class A Common Stock (MRVI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Kimco Realty Corporation (HC) Common Stock vs Maravai LifeSciences Holdings Inc. Class A Common Stock — how do they compare? Kimco Realty Corporation (HC) Common Stock trades at $22.59 (market cap $15.02B), while Maravai LifeSciences Holdings Inc. Class A Common Stock trades at $6.56 (market cap $977.37M). The key difference: Kimco Realty Corporation (HC) Common Stock is far larger — about 15.4× Maravai LifeSciences Holdings Inc. Class A Common Stock's market cap, and Kimco Realty Corporation (HC) Common Stock pays a 5% dividend while Maravai LifeSciences Holdings Inc. Class A Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Kimco Realty Corporation (HC) Common Stock for 6 Days and Maravai LifeSciences Holdings Inc. Class A Common Stock for 0 Days on average.
| KIM | MRVI | |
|---|---|---|
Market Cap | $15.02B | $977.37M |
Volume | 4,636,202 | 2,742,564 |
Sector | Real Estate | Health |
52-Week High | $26.38 | $9.00 |
52-Week Low | $19.78 | $2.83 |
Typical Hold Time | 6 Days | 0 Days |
Enterprise Value | $23.18B | $1.08B |
Dividend Yield | 5% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
KIM trades at $22.45, up 0.58% today, with a bearish technical signal from moving averages but neutral oscillators. The company reported strong earnings beats in recent quarters, with Q3 2026 results expected soon. Fundamentals show robust profitability with a 27.76% net income margin and a P/E of 26.1. Analyst consensus is a Buy with a $26.09 price target, though technical indicators suggest near-term caution.
The outlook for KIM is mixed; strong fundamentals and positive analyst sentiment support upside, but technical bearishness and macroeconomic risks pose challenges. Investment opportunity lies in its high dividend yield and earnings growth, while risks include market volatility and real estate sector headwinds. The stock's performance will hinge on upcoming earnings and broader economic conditions.
Maravai LifeSciences (MRVI) trades at $6.53, down 7.51% in the last session amid mixed signals. The stock shows improving fundamentals with Q2 2026 revenue growth of 9% and three consecutive earnings beats, though it remains unprofitable with a -37.07% net margin. Technical analysis indicates neutral positioning with key support at $6 and resistance at $7. Recent news highlights patent expansions in China and institutional accumulation.
The outlook remains cautiously optimistic with analyst consensus pointing to 7% upside potential to the $7.00 price target. Key opportunities include margin expansion and RNA technology leadership, while risks center on persistent cash burn and competitive pressures in life sciences. The stock offers speculative growth potential for risk-tolerant investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Kimco Realty Corporation (HC) Common Stock
Kimco Realty is a real estate investment trust that owns and operates open-air, grocery-anchored shopping centers and mixed-use properties in the United States.
Read more on KIM →About Maravai LifeSciences Holdings Inc. Class A Common Stock
Maravai LifeSciences Holdings Inc. is a life sciences company supporting drug therapy, diagnostic, and vaccine development through four operating brands: TriLink BioTechnologies (nucleic acid and mRNA synthesis), Cygnus Technologies (biologics safety testing), Glen Research (oligonucleotide synthesis materials), and Alphazyme (enzyme manufacturing). It serves biotech and biopharma customers from discovery through commercial manufacturing.
Read more on MRVI →
